“PRECISION MEDICINE is driving the most exciting and powerful advances in cancer care today, particularly in lung cancer. It’s encouraging to see that next-generation genetic testing tools can help physicians and their patients get the crucial genomic information needed to make treatment decisions, at a faster pace and lower cost than with other approaches,” said ASCO President Bruce E. Johnson, MD, FASCO, at a press briefing, where the study was presented in advance of the ASCO Annual Meeting.
“Next-generation sequencing panels with between 50 and 400 genes yield much more information, with a cost that’s competitive or lower than standard testing,” he commented during the press briefing. ■
DISCLOSURE: Dr. Johnson has received research funding from Novartis and Toshiba and has patents and other intellectual property with royalties from Dana-Farber Cancer Institute.
Nathan A. Pennell, MD, PhD
AN ECONOMIC model comparing different types of genetic testing in metastatic non–small cell lung cancer (NSCLC) found using next-generation sequencing to test for all known lung cancer–related gene changes at the time of diagnosis was less costly and faster than...